255 related articles for article (PubMed ID: 33888600)
1. Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
El Meskini R; Atkinson D; Kulaga A; Abdelmaksoud A; Gumprecht M; Pate N; Hayes S; Oberst M; Kaplan IM; Raber P; Van Dyke T; Sharan SK; Hollingsworth R; Day CP; Merlino G; Weaver Ohler Z
Mol Cancer Res; 2021 Aug; 19(8):1422-1436. PubMed ID: 33888600
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
3. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
[TBL] [Abstract][Full Text] [Related]
4. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
5. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
8. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
9. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
10. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
11. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Nagato T; Lee YR; Harabuchi Y; Celis E
Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.
Mony JT; Zhang L; Ma T; Grabosch S; Tirodkar TS; Brozick J; Tseng G; Elishaev E; Edwards RP; Huang X; Vlad AM
Cancer Immunol Immunother; 2015 Sep; 64(9):1095-108. PubMed ID: 25998800
[TBL] [Abstract][Full Text] [Related]
14. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
Naidus E; Bouquet J; Oh DY; Looney TJ; Yang H; Fong L; Standifer NE; Zhang L
Cancer Immunol Immunother; 2021 Jul; 70(7):2095-2102. PubMed ID: 33420629
[TBL] [Abstract][Full Text] [Related]
15. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
17. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
19. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
20. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
